Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHelios Underw Regulatory News (HUW)

Share Price Information for Helios Underw (HUW)

Share Price is delayed by 15 minutes
Get Live Data
214.50    -8.00 (-3.60%)
Bid:
211.00
Ask:
218.00
Spread: 7.00 (3.318%)
Market Cap: £146.53m
HUW Live PriceLast checked at - London Stock Exchange

Intraday Helios Underw Share Chart

PDMR Dealing

29 Aug 2025 12:52

RNS Number : 2778X
Helios Underwriting Plc
29 August 2025
 

29 August 2025

 

Helios Underwriting plc

('Helios' or 'the Company')

 

Joint Share Ownership Plan

PDMR Dealing

 

Sale of JSOP Shares

 

Helios, the only publicly traded company offering instant access to a diverse portfolio of syndicates at Lloyd's of London,  the world's largest insurance market, announces that on 28 August 2025, a number of ordinary shares of 10 pence each ("Ordinary Shares") were sold by a PDMR as further described below pursuant to the Helios Underwriting Plc Employees' Joint Share Ownership Plan (the "JSOP") ("JSOP Shares").

 

The JSOP Shares were jointly held with JTC Employer Solutions Trustee Limited (as trustee of the Helios Underwriting Plc Employees' Share Trust (the "Trust") as co-owner ("JSOP Co-Owner") of the JSOP Shares pursuant to the terms of the JSOP.

 

Details of the related original subscription of Ordinary Shares in respect of the JSOP and the terms of the JSOP were previously disclosed in RNS issued on 14 December 2017 and 17 August 2021 respectively and were also disclosed in the Company's Annual Report and Accounts.

 

Below is a table declaring the interests that the PDMR sold:

 

Name of PDMR

Date of related JSOP Award

Number of JSOP Shares held prior to transaction

Number of JSOP Shares sold at £2.02 per share in which the PDMR had an interest*

Number of JSOP Shares in which PDMR retains an interest

Nigel Hanbury

13th December 2017

300,000

300,000

Nil

Nigel Hanbury

16th August 2021

322,500

134,552**

Nil

 

*Pursuant to the terms of the JSOP, the total sale proceeds of £877,795 were split £194,927 to Mr Hanbury and the balance to the JSOP Co-Owner. The nature of the JSOP being that the participants receive the growth in value above associated hurdles.

*\* The 16th August 2021 JSOP Award vested at this level.

 

Further to the JSOP related transactions, Nigel Hanbury is now interested in 8,907,225 Ordinary Shares representing 11.38% of the Company's issued share capital.

 

The JSOP Shares were sold to JTC Employer Solutions Trustee Limited as trustee of the Trust. The Trust is a market standard discretionary employee benefit trust.

 

The Trust purchased the JSOP Shares (together with an additional 315,778 Ordinary Shares sold at the same time by a former PDMR JSOP participant) with loan funding provided by Helios and the resulting Ordinary Shares are now held in the Trust.

 

The Ordinary Shares now held in the Trust (remaining at 1,100,000 Ordinary Shares further to the purchases made by the Trust and it exercising a call option over the unvested JSOP shares) are available to the Trust for trust purposes (including therefore for use in connection with future maturities under the Company's Long Term Incentive Plan).

 

Loan funding

 

The loan funding by Helios to the Trust in relation to the sales noted above in connection with JSOP (including in respect of sales made at the same time by a former PDMR JSOP participant) was £ 1,515,667. Additional loan funding of £305,320.97 was also provided by Helios to the Trust at the same time.

 

A sum of £1,182,213 was immediately credited back to Helios by the Trust equating to the proceeds accrued to the JSOP Co-Owner under the JSOP and was applied by Helios towards payment of the outstanding subscription price in relation to the Ordinary Shares that had been held under the JSOP.

 

The loan to the Trust constituted a related party transaction for the purposes of AIM Rule 13. The independent directors being John Chambers, Adhiraj Maitra, Andrew Christie, Tom Libassi and Katie Wade, having consulted with the Company's nominated adviser Deutsche Numis, confirm that they consider that the terms of the loan are fair and reasonable insofar as the Company's shareholders are concerned.

The information set out below is provided in accordance with the requirements of Article 19 of the UK Market Abuse Regulation and AIM Rule 17.

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Nigel Hanbury

2

Reason for Notification

a)

Position/status

Non-Executive Deputy Chairman

b)

Initial notification/Amendment

Initial Announcement

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Helios Underwriting plc

b)

LEI

213800FX86DJW5TCM864

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of 10 pence each

ISIN - GB00B23XLS45

b)

Nature of the transaction

Sales of interests in Ordinary Shares pursuant to the Helios Underwriting Plc Employees' Joint Share Ownership Plan.

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

£2.02 per share

434,552

 

 

Pursuant to the terms of the JSOP, the total sale proceeds of £877,795 were split £194,927 to Mr Hanbury and the balance to the JSOP Co-Owner (JTC Employer Solutions Trustee Limited). The nature of the JSOP being that the participants receive the growth in value above associated hurdles.

d)

Aggregated information

- Aggregated volume

- Price

 

Not applicable - single transaction

Nil

e)

Date of the transaction

28 August 2025

f)

Place of the transaction

Outside of a trading venue

 

 

 

For further information, please contact:

Helios Underwriting plc

John Chambers - Interim Executive Chairman +44 (0)203 965 6441 

Adhiraj Maitra - Director of Finance and Operations +44 (0)203 743 2114

 

Deutsche Numis (Nomad and Broker)

Giles Rolls / Charles Farquhar +44 (0)20 7601 6100

 

FTI Consulting

Ed Berry +44 (0)7703 330 199

Nathan Hambrook-Skinner +44 (0)7977 817 092

Christian Harte +44 (0)7974 288 763

 

About Helios

Helios provides a limited liability direct investment into the Lloyd's insurance market and is quoted on the London Stock Exchange's AIM market (ticker: HUW). Helios trades within the Lloyd's insurance market. The portfolio provides a broad spread of business primarily participating in the US and other international wholesale and reinsurance markets. For further information please visit www.huwplc.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUKVARVRUWUAR
Date   Source Headline
1st Jun 20267:00 amRNSTotal Voting Rights
1st Jun 20267:00 amRNSTransaction in Own Shares
27th May 20267:00 amRNSNotice of AGM
26th May 20267:00 amRNSTransaction in Own Shares
21st May 20267:00 amRNSFinal Results for the year ended 31 December 2025
18th May 20267:00 amRNSTransaction in Own Shares
14th May 20267:00 amRNSTR-1 announcement
11th May 20267:00 amRNSTransaction in Own Shares
5th May 20267:00 amRNSTransaction in Own Shares
1st May 20267:00 amRNSTotal Voting Rights
27th Apr 20267:00 amRNSTransaction in Own Shares
22nd Apr 20267:00 amRNSTR-1: Acquisition of Voting Rights
21st Apr 20267:00 amRNSChange of Nominated Adviser
20th Apr 20267:00 amRNSTransaction in Own Shares
14th Apr 20265:17 pmRNSHolding(s) in Company
10th Apr 20267:00 amRNSDirector/PDMR Shareholding
9th Apr 20267:00 amRNSQuarterly Syndicate Mid-point Forecast update
20th Jan 20267:00 amRNS2026 YOA Portfolio Update
9th Jan 20267:00 amRNSAppointment of Chief Underwriting Officer
4th Dec 20255:42 pmRNSGrant of LTIP Awards
2nd Dec 20257:00 amRNSNet Asset Value(s)
13th Nov 20251:32 pmRNSDirector/PDMR Shareholding
13th Nov 20251:30 pmRNSDirector/PDMR Shareholding
7th Nov 202510:10 amRNSHolding(s) in Company
6th Nov 20251:51 pmRNSDirector/PDMR Shareholding
5th Nov 20255:48 pmRNSTR1 - Change in breakdown of voting rights
30th Oct 20257:00 amRNSResult of Tender Offer
24th Oct 202512:20 pmRNSResults of General Meeting
21st Oct 20257:01 amRNSDirector Appointments
21st Oct 20257:00 amRNSCapital Markets Day
29th Sep 20257:01 amRNSProposed Tender Offer and Notice of GM
29th Sep 20257:00 amRNSHalf Year Results
19th Sep 20257:00 amRNSAppointment of Chief Executive Officer
1st Sep 20253:37 pmRNSDirector/PDMR Shareholding
29th Aug 202512:52 pmRNSPDMR Dealing
28th Aug 20252:16 pmRNSDirector/PDMR Shareholding
26th Aug 20257:00 amRNSQuarterly Syndicate Mid-point Forecasts
1st Aug 20257:00 amRNSTotal Voting Rights
31st Jul 202512:12 pmRNSTR-1: Notification of major holdings
18th Jul 20257:00 amRNSResults of Scrip Dividend Election
9th Jul 20259:45 amRNSResults of Scrip Dividend Election
30th Jun 20255:40 pmRNSAppointment of Executive Director
30th Jun 202512:28 pmRNSResult of AGM
30th Jun 20257:00 amRNSChange of Nominated Adviser
20th Jun 20259:32 amRNSScrip Dividend Reference Price
9th Jun 20251:15 pmRNSLTIP Exercise and Total Voting Rights Update
9th Jun 20251:15 pmRNSGrant of LTIP Awards
2nd Jun 20257:00 amRNSPosting of Annual Report and Notice of AGM
2nd Jun 20257:00 amRNSFinal results for the year ended 31 December 2024
29th May 20257:06 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.